Clinical drug development using dynamic biomarkers to enable personalized health care in Chronic Obstructive Pulmonary Disease
Research output: Contribution to journal › Review › Research › peer-review
Despite massive investments in development of novel treatments for heterogeneous diseases such as Chronic Obstructive Pulmonary Disease (COPD), the resources spent have only benefitted a fraction of the population treated. Personalized Health Care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution. In this review, we discuss past successes and failures in drug development and biomarker research in COPD. We describe research in COPD phenotypes, and the required characteristics of a suitable biomarker for identifying patients at higher risk of progression. We review the role of extra-cellular matrix proteins found to be upregulated in COPD. Novel biomarkers of connective tissue remodeling which may provide added value for a personalized approach by detecting subgroups of patients with active disease suitable for pharmacological intervention are discussed.
Original language | English |
---|---|
Journal | Chest |
Volume | 148 |
Issue number | 1 |
Pages (from-to) | 16-23 |
Number of pages | 8 |
ISSN | 0012-3692 |
DOIs | |
Publication status | Published - Jul 2015 |
ID: 135784413